General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden

被引:0
|
作者
Kim, Kun [1 ]
Sweeting, Michael [2 ]
Wilking, Nils [3 ]
Joensson, Linus [4 ]
机构
[1] Karolinska Inst, Dept Neurobiol Care Sci & Soc, BioClinicum J9 20, Stockholm, Sweden
[2] AstraZeneca Nord AB, Hlth Econ, Stockholm, Sweden
[3] AstraZeneca, Stat Innovat, Cambridge, England
[4] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
关键词
survival extrapolation; general population mortality adjustment; excess hazard models; standard parametric distribution models; economic evaluation; CURE FRACTION; MODELS;
D O I
10.1177/0272989X241275969
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background In economic evaluations of novel therapies, assessing lifetime effects based on trial data often necessitates survival extrapolation, with the choice of model affecting outcomes. The aim of this study was to assess accuracy and variability between alternative approaches to survival extrapolation.Methods Data on HER2-positive breast cancer patients from the Swedish National Breast Cancer Register were used to fit standard parametric distribution (SPD) models and excess hazard (EH) models adjusting the survival projections based on general population mortality (GPM). Models were fitted using 6-y data for stage I and II, 4-y data for stage III, and 2-y data for stage IV cancer reflecting an early data cutoff while maintaining sufficient events for comparison of model estimates with actual long-term outcomes. We compared model projections of 15-y survival and restricted mean survival time (RMST) to 15-y registry data and explored the variability between models in extrapolations of long-term survival.Results Among 11,224 patients compared with the observed registry 15-y RMST estimates across the disease stages, EH cure models provided the most accurate estimates in patients with stage I to III cancer, whereas EH models without cure most closely matched survival in patients with stage IV cancer, in which cure assumption was less plausible. The Akaike information criterion-averaged model projections varied as follows: -8.2% to +5.3% for SPD models, -4.9% to +5.2% for the EH model without a cure assumption, and -19.3% to -0.2% for the EH model with a cure assumption. EH models significantly reduced between-model variance in the predicted RMSTs over a 50-y time horizon compared with SPD models.Conclusions EH models may be considered as alternatives to SPD models to produce more accurate and plausible survival extrapolation that accounts for general population mortality.
引用
收藏
页码:843 / 853
页数:11
相关论文
共 50 条
  • [1] Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis
    Dendukuri, Nandini
    Khetani, Karim
    McIsaac, Michelle
    Brophy, James
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (10) : 1429 - 1434
  • [2] Cost-Effectiveness Analysis Of Pertuzumab For Metastatic Her2-Positive Breast Cancer In Japan
    Tange, C.
    Kunisawa, S.
    Maeda, S.
    Shimozuma, K.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A456 - A457
  • [3] Cost-effectiveness of adjuvant chemotherapy plus trastuzumab (T) in HER2-positive breast cancer
    Liberato, N. L.
    Marchetti, M.
    Barosi, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI6 - XI6
  • [4] PRELIMINARY ANALYSIS OF THE COST-EFFECTIVENESS OF PERTUZMAB IN PATIENTS WITH HER2-POSITIVE BREAST CANCER IN JAPAN
    Uechi, S.
    Moriwaki, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [5] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    [J]. CANCER, 2007, 110 (03) : 489 - 498
  • [6] The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
    Antonazzo, Ippazio Cosimo
    Cortesi, Paolo Angelo
    Sopo, Gerardo Miceli
    Mazzaglia, Giampiero
    Conte, Pierfranco
    Mantovani, Lorenzo Giovanni
    [J]. CANCERS, 2023, 15 (04)
  • [7] Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis
    Khoirunnisa, Sudewi Mukaromah
    Suryanegara, Fithria Dyah Ayu
    Setiawan, Didik
    Postma, Maarten Jacobus
    de Jong, Lisa Aniek
    [J]. PLOS ONE, 2024, 19 (05):
  • [8] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes
    Hassett, M. J.
    Li, H.
    Burstein, H. J.
    Punglia, R. S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 43 - 51
  • [10] Trastuzumab (Herceptin®) for treatment of HER2-positive metastatic breast cancer:: a cost-effectiveness analysis.
    Hornberger, J
    Foutel, V
    Kerrigan, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S136 - S136